MS‐LE vs S‐LE
- Alternative lipid emulsions versus pure soy oil based lipid emulsions for parenterally fed preterm infants 2015 · Cochrane Headline outcomes onlyno estimate extracted1 study · 60 participantsVery low
It is very uncertain whether MS‐LE changes bronchopulmonary dysplasia/chronic lung disease compared with S‐LE (very low certainty).
It is very uncertain whether MS‐LE changes any sepsis (clinical and/or culture positive) compared with S‐LE (very low certainty).
All fish oil containing LE showed no clear difference in death before discharge compared with S‐LE (low certainty).
All fish oil containing LE showed no clear difference in bronchopulmonary dysplasia/chronic lung disease compared with S‐LE (low certainty).
All fish oil containing LE showed no clear difference in any sepsis (clinical and/or culture positive) compared with S‐LE (low certainty).
All fish oil containing LE showed no clear difference in retinopathy of prematurity (≥ stage 3) compared with S‐LE (low certainty).
All alternative LE showed no clear difference in death before discharge compared with S‐LE (low certainty).
It is very uncertain whether all alternative LE changes any sepsis (clinical and/or culture positive) compared with S‐LE (very low certainty).
MOFS‐LE showed no clear difference in bronchopulmonary dysplasia/chronic lung disease compared with S‐LE (low certainty).
It is very uncertain whether all alternative LE changes retinopathy of prematurity (≥ stage 3) compared with S‐LE (very low certainty).
MOFS‐LE showed no clear difference in any sepsis (clinical and/or culture positive) compared with S‐LE (low certainty).
MOFS‐LE showed no clear difference in retinopathy of prematurity (≥ stage 3) compared with S‐LE (low certainty).
MFS‐LE showed no clear difference in death before discharge compared with S‐LE (low certainty).